• Quantum technology development advanced, including improved readout and magnetic sensing capabilities
• Biochip development accelerated through partnership with IMEC, potassium testing improved to meet lab standards
• Strong cash position of $11.6 million to fund R&D and commercial activities

Archer Materials Limited, a quantum technology company, provided its Quarterly Activities Report and Appendix 4C for the quarter ended 30 September 2025. The company reported progress in its core technology development areas. In quantum technologies, the 12CQ project team improved the readout of quantum information and strengthened the chip's magnetic sensing capabilities, demonstrating electrical detection of magnetic resonance. This is a critical milestone towards a qubit demonstration in 2026. The company also advanced its Tunnel Magnetoresistance (TMR) sensor technology to operate at cryogenic temperatures, enabling potential applications in quantum computing, defence, aerospace, and navigation. In the Biochip development, Archer partnered with IMEC to accelerate the project, including benchmarking silicon-based biochips against graphene. The team also made significant improvements in measuring the accuracy of potassium levels in blood, meeting clinical lab standards. The biochip sensing platform is designed to be adaptable to detect other ions of interest. Archer maintained a strong cash position of $11.6 million at the end of the quarter, with no debt, to fund its ongoing R&D and commercial activities.

Archer is focused on advancing its quantum technology and biochip development, with plans to produce a full handheld biochip prototype in 2026 for use in a pilot clinical trial. The company is also exploring the adaptability of the biochip platform to detect other ions beyond potassium.